First Author | Montecino-Rodriguez E | Year | 1996 |
Journal | J Immunol | Volume | 157 |
Issue | 8 | Pages | 3334-40 |
PubMed ID | 8871629 | Mgi Jnum | J:38361 |
Mgi Id | MGI:85732 | Doi | 10.4049/jimmunol.157.8.3334 |
Citation | Montecino-Rodriguez E, et al. (1996) Defective B cell development in Snell dwarf (dw/dw) mice can be corrected by thyroxine treatment. J Immunol 157(8):3334-40 |
abstractText | Snell dwarf (dw/dw) mice are deficient in anterior pituitary hormones due to a mutation in the gene encoding the Pit-1 transcription factor. Bone marrow B cell development is also suppressed in the mice, providing circumstantial evidence that one or more anterior pituitary-derived products, or factors induced by them, are required for normal B lymphopoiesis. However, concluding that this is the case is dependent on showing that hormonal treatment of dwarf mice reverses their B cell defects. dw/dw mice were treated with growth hormone (GH), insulin-like growth factor-I (IGF-I), or thyroxine in an attempt to restore bone marrow B lymphopoiesis. GH and IGF-I increased the number of B lineage cells in the bone marrow and spleen but did not restore the frequency of bone marrow pre-B cells to normal. However, bone marrow cellularity in thyroxine-treated dw/dw mice was comparable to that in control animals, and both the frequency and absolute number of B lineage cells had increased to normal or even above normal. Taken together, these data indicate that endocrine factors, especially those regulated by the hypothalamic-pituitary-thyroid axis, are potent B lymphopoietic factors. |